White Paper
Continuous Supplier Oversight in a Falsification Era: Closing the Gap Between Audits
Executive Summary
Supplier oversight is becoming increasingly complex for pharmaceutical, biotechnology, and other FDA-regulated organizations that rely on contract manufacturers, laboratories, and critical suppliers. Traditional supplier quality management practices, including periodic audits and questionnaires, may leave significant gaps between formal reviews as regulatory status, performance, and data integrity risks change.
This white paper examines how continuous supplier oversight and a risk-based supplier management approach can help organizations strengthen GMP compliance and identify potential supplier risks earlier. It explores pharmaceutical supplier risk management, data integrity in outsourced operations, quality agreements, regulatory monitoring, and supplier audit practices designed to provide greater visibility into the partners responsible for critical products and data.
Download This White Paper
Fill out the form to receive our White Paper.
